Arovella Therapeutics Ltd (ASX:ALA) CEO and managing director Dr Michael Baker joins proactive in the virtual studio to highlight the company’s clinical partnership with emerging oncolytic virus-focused BioTech company Imugene Ltd (ASX:IMU, OTC:IUGNF). ALA’s recent strategic review has also refocused the company on its invariant Natural Killer T (iNKT) cell platform, a platform with potential to address blood cancers and solid tumours.
#ASX #ProactiveInvestors #ArovellaTherapeutics #BioTech #Oncology